Monte Rosa Therapeutics, Inc. Accrued Liabilities, Current
Monte Rosa Therapeutics, Inc. (GLUE) had Accrued Liabilities, Current of $25.77 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $25.77M.
- 2026-03-31: Accrued Liabilities, Current $25.59M.
- 2025-12-31: Accrued Liabilities, Current $26.69M.
- 2024-12-31: Accrued Liabilities, Current $18.79M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $25.77M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $25.59M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $26.69M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $18.79M 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |